Growth • AbbVie
ABBV
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
11,1%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
-1,7%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
-11,5%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
-14,7%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
-7,3%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
7,1%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!